NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NA
Post# of 325
(Total Views: 221)
Posted On: 03/17/2022 4:00:46 PM
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Significant Milestone in Advancing Berubicin
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently participated in the Virtual Investor 2022 Top Picks Conference. The company’s CEO John Climaco provided a corporate presentation and participated in a moderated questions and answer session during the event. Berubicin, a novel anthracycline and the first in its drug class to appear to cross the blood-brain barrier, is CNS Pharmaceuticals’ lead drug candidate. “The company is currently developing treatments using Berubicin for serious brain and central nervous system oncology indications, including glioblastoma multiforme (‘GBM’), an aggressive and incurable form of cancer in the brain,” reads a recent article. The piece further discusses CNS Pharmaceuticals’ receipt of approval from swissethics, the umbrella organization of the cantonal Ethics Committee in Switzerland, for a pivotal Berubicin study for GBM. “Receiving approval from swissethics is a significant milestone for the company. Our stated goal is, and always has been, to see Berubicin approved for the treatment of glioblastoma, and this means globally,” Climaco said. “This terrible disease does not discriminate on the basis of geography or anything else: Patients in Europe are as desperate as patients in the United States, and treating patients is not only why we do what we do, but how we do it as well.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently participated in the Virtual Investor 2022 Top Picks Conference. The company’s CEO John Climaco provided a corporate presentation and participated in a moderated questions and answer session during the event. Berubicin, a novel anthracycline and the first in its drug class to appear to cross the blood-brain barrier, is CNS Pharmaceuticals’ lead drug candidate. “The company is currently developing treatments using Berubicin for serious brain and central nervous system oncology indications, including glioblastoma multiforme (‘GBM’), an aggressive and incurable form of cancer in the brain,” reads a recent article. The piece further discusses CNS Pharmaceuticals’ receipt of approval from swissethics, the umbrella organization of the cantonal Ethics Committee in Switzerland, for a pivotal Berubicin study for GBM. “Receiving approval from swissethics is a significant milestone for the company. Our stated goal is, and always has been, to see Berubicin approved for the treatment of glioblastoma, and this means globally,” Climaco said. “This terrible disease does not discriminate on the basis of geography or anything else: Patients in Europe are as desperate as patients in the United States, and treating patients is not only why we do what we do, but how we do it as well.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)CNS Pharmaceuticals Inc. (CNSP) Stock Research Links
Scroll down for more posts ▼